Public health. A sound rationale needed for phase III HIV-1 vaccine trials

Science. 2004 Jan 16;303(5656):316. doi: 10.1126/science.1094620.

Affiliation

¹ Scripps Research Institute, La Jolla, California, USA.

PMID: 14726576
DOI: 10.1126/science.1094620

No abstract available

MeSH terms

AIDS Vaccines / immunology*
Clinical Trials, Phase III as Topic* / economics
Costs and Cost Analysis
HIV Envelope Protein gp120 / immunology*
HIV Infections / immunology*
HIV Infections / prevention & control
HIV Infections / therapy
HIV-1 / immunology*
Humans
Immunization Schedule
Immunization, Secondary
T-Lymphocytes, Cytotoxic / immunology
T-Lymphocytes, Helper-Inducer / immunology
Thailand
United States
Vaccines, Synthetic / immunology

Substances

AIDS Vaccines
HIV Envelope Protein gp120
Vaccines, Synthetic